Who owns Oracal?
Oracal is owned by Birzeit Pharmaceutical (Palestine, PEX: BPC).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Evidence: Birzeit Pharmaceutical Company — over-the-counter products. Last checked .
Key facts
- Current owner
- Birzeit Pharmaceutical Company reported
- Owner HQ
- 🇵🇸 Palestine, Birzeit
- Origin
- 🇵🇸 Palestine
- Category
- Consumer health › Over-the-counter medicine › Digestive health
- Parent ticker
- PEX: BPC
- Last verified
- · 1 sources
About Oracal
Oracal is a 600 mg calcium carbonate tablet, equivalent to 240 mg of calcium, and the company files it under both hyperacidity and vitamins because it is sold as an antacid and as a calcium supplement at once. As an antacid the dose is one or two tablets after each meal; as a supplement it is three tablets a day for children and adults and five for adolescents, pregnant women and nursing mothers.
Ownership timeline of Oracal
- Current owner Birzeit Pharmaceutical [1] reported
Where Oracal sits in Birzeit Pharmaceutical
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Birzeit Pharmaceutical ownership tree →
See the full Birzeit Pharmaceutical brand portfolio (8) →
Other brands owned by Birzeit Pharmaceutical
Birzeit Pharmaceutical controls 8 brands on Brandtree, 5 of them in consumer health.
Also in consumer health
Other brands in digestive health, and who owns them
The 25 brands in digestive health on Brandtree belong to 18 owners. The largest is Bayer, with 2.
| Brand | Owner | Owner based in |
|---|---|---|
| Alka-Seltzer | Bayer | 🇩🇪 Germany |
| Daiichi Sankyo Stomach Medicine | Daiichi Sankyo Healthcare | 🇯🇵 Japan |
| Kaopectate | Genomma Lab | 🇲🇽 Mexico |
| Epocler | Hypera | 🇧🇷 Brazil |
| Entrostop | Kalbe Farma | 🇮🇩 Indonesia |
| Metamucil | Procter & Gamble | 🇺🇸 United States |
| Buscolysin | Sopharma | 🇧🇬 Bulgaria |
| First Response | Church & Dwight | 🇺🇸 United States |
About the owner: Birzeit Pharmaceutical
Birzeit Pharmaceutical is a publicly listed company headquartered in Birzeit, Palestine, founded in 1974. Brandtree records 8 brands under its control, and it is listed as PEX: BPC.
Birzeit Pharmaceutical Company is a Palestinian generic drug maker founded in 1974 in Birzeit, a town about ten kilometres from Ramallah. It started as a private joint stock company with $150,000 of capital and became a public joint stock company in 1979; its shares trade on the Palestine Exchange. It makes around 270 products across 16 production lines at four locations and says it carries roughly 170 brand names. It supplies the Palestinian Ministry of Health alongside pharmacies and doctors, and exports mainly to Eastern Europe. Most of its output is prescription-only; the brands listed here are the ones it sells over the counter.
Birzeit Pharmaceutical: full profile, brands and acquisition history →
🇵🇸 Oracal and other Palestinian brands
Brandtree records a controlling owner for 9 brands that began in Palestine. 1 of them (11%) are now controlled by a company headquartered in another country; Oracal is not one of them.
- Siniora — Siniora 🇯🇴
Frequently asked questions
Who is the parent company of Oracal?
The parent company of Oracal is Birzeit Pharmaceutical, a publicly listed company headquartered in Palestine.
Is Oracal Palestinian?
Yes. Oracal originated in Palestine and its owner, Birzeit Pharmaceutical, is also headquartered in Palestine.
Is Oracal still owned by Birzeit Pharmaceutical?
Yes. As of 22 September 2026, Oracal is still owned by Birzeit Pharmaceutical. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Birzeit Pharmaceutical Company — over-the-counter products — Birzeit Pharmaceutical Company, Official document; retrieved 22 September 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.